HR+ refers to a subtype of breast cancer that tests positive for hormone receptors, specifically estrogen and/or progesterone. This means that the cancer cells grow in response to these hormones, making hormone therapy a common treatment option. Patients with HR+ breast cancer may benefit from medications that block hormone production or action, such as tamoxifen or aromatase inhibitors. This targeted approach can help slow down or stop the growth of the cancer, improving outcomes for many individuals diagnosed with this subtype.